Neurology & CNS Therapeutics · Prescription Drugs
Biogen: Funding & valuation
Biogen has $1M paid in by investors, lenders and donors.
Financials
Revenue of $9.9B in 2025. +2.2% on the year before. Net income $1.3B.
$9.9BRevenue2025 · +2.2%
$1.3BNet income2025 · −20.8%
Revenue by yearas filed, with the net income
Sources: SEC
Money
Biogen has $1M paid in by investors, lenders and donors.
$1MPaid in
$864MIncome taxes paidFY2025
$153.8MCapital expenditureFY2025
StagePaidSignedAnnouncedSourceFiledAnnouncedPress
Money in
$1MPaid
From its filingssec.gov ↗
| FY2023 | FY2024 | FY2025 | |
|---|---|---|---|
| Income taxes paid | $740.7M | $355.1M | $864M |
| Shares bought back | – | – | – |
| Capital expenditure | $277M | $153.7M | $153.8M |
| Stock-based compensation | $264.2M | $291.2M | $290.8M |
| Acquisitions, net of cash | $6.9B | $1.1B | – |
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".
